Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This Phase 1 clinical trial will assess the safety, tolerability and pharmacokinetics (PK) of
a solid capsule form of NTP42:KVA4 in male and female healthy volunteers. In a randomised,
3-way cross-over study, the Trial will involve 3 dose sessions where all volunteers will
receive 3 single doses of NTP42:KVA4. In two of the dose sessions, volunteers will be fasted
where, in one, they will be given the NTP42:KVA4 capsule and, in another, they will be given
NTP42:KVA4 in oral liquid form. To test the effect of food on drug absorption (PK), the
volunteers will also be given the NTP42:KVA4 capsule after eating a full breakfast.